---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-004603"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:25:13.497272+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Celldex Q2 net loss $0.54 per share; Phase 3 CSU program launched

## Summary
- Net loss $35.8M ($0.54/share) vs $30.5M loss in Q2 2023; revenue $2.5M, up from $0.3M.
- Cash $802.3M as of June 30; sufficient to fund operations through 2027.
- Initiated global Phase 3 CSU trials (EMBARQ-CSU1/2) in July 2024; actively enrolling.
- Phase 2 CIndU study met primary endpoint (negative provocation test) at Week 12; full data 2H 2024.
- Barzolvolimab Phase 2 studies ongoing in PN, EoE; AD study to start YE 2024; bispecific CDX-622 enters clinic in 2024.

## SEC filing metadata
- accession: 0001171843-24-004603
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000117184324004603/0001171843-24-004603-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000117184324004603/f8k_080824.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-004603
- JSON: https://secwatch.observer/filing/0001171843-24-004603.json
- Plain text: https://secwatch.observer/filing/0001171843-24-004603.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.